Mechanistically, the bone marrow stroma confers venetoclax resistance by reducing the primary AML cells’ BCL-2 dependency with decreased BCL-2 expression and increased BCL-xL and BCL-xS expression. Here, BCL2L1 is linked to acute myeloid leukemia.